Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.
Product Name : Uzpruvo
Product Type : Antibody
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Efficacy and safety data from the Effisayil™ 1 trial showed rapid pustular and skin clearance was sustained over 12 weeks in patients with GPP flares treated with spesolimab, selective antibody that blocks the activation of the interleukin-36 receptor ...
Product Name : Spevigo
Product Type : Antibody
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Bioeq IP AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgari...
Product Name : FYB202
Product Type : Antibody
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Bioeq IP AG
Deal Size : Inapplicable
Deal Type : Inapplicable